Gubra A/S (CPH: GUBRA)
Denmark
· Delayed Price · Currency is DKK 616.00
+44.00 (7.69%)
Nov 20, 2024, 4:59 PM CET
418.52% (1Y)
| Market Cap | 9.88B |
| Revenue (ttm) | 223.82M |
| Net Income (ttm) | -46.53M |
| Shares Out | 16.31M |
| EPS (ttm) | -2.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,928 |
| Open | 574.00 |
| Previous Close | 572.00 |
| Day's Range | 570.00 - 620.00 |
| 52-Week Range | 113.94 - 754.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 28, 2025 |
About Gubra
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformat... [Read more]
Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 220
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol GUBRA
Financial Performance
Financial StatementsNews
Danish Biotech Gubra Says Obesity Drug Positive in Early Trial
Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, clearing a crucial early hurdle.
8 days ago - BNN Bloomberg